1. 首页
  2. ›Seven Innovent Biologics Innovative Drugs Included in 2026 National Medical Insurance Directory

Seven Innovent Biologics Innovative Drugs Included in 2026 National Medical Insurance Directory

N
nashnova research
·2026-11-15发布·阅读约 9 分钟

Innovent Biologics (01801) placed seven innovative drugs on China's 2026 national medical insurance catalogue — four of them for the first time — lifting its reimbursed total to 17 products. The paywall is down; the real test is whether prescriptions follow.

01

Which drugs made it in?

•
Four first-time entries: weight-loss/metabolic drug Xinermei® (mazdutide), a GCG/GLP-1 dual-receptor agonist — an injection that activates two gut-hormone receptors to control blood sugar and body weight; autoimmune drug Xinmeiyue® (picankibart), an IL-23p19 inhibitor; immuno-oncology drug Dabaixing® (ipilimumab), a CTLA-4 inhibitor; and blood-cancer drug Weifutai® (quizartinib), a type-II FLT3 inhibitor.
•
Two existing drugs added new indications: PD-1 flagship Tyvyt® (sintilimab) and BTK inhibitor Jiepali® (pirtobrutinib). Cholesterol drug Xinbile® (tafolecimab) renewed its listing.
•
This means → Innovent secured four "new entry tickets" plus three "expansion tickets" in a single round — seven drugs landed at once, spanning oncology, cardio-metabolic, and autoimmune diseases.
02

What do 17 listed drugs mean?

•
Including these seven, Innovent now has 17 innovative drugs on the national reimbursement list. The company says it has cumulatively served over 20 million patients.
•
In plain terms = the reimbursement catalogue is a drugmaker's "sales pass" — once a drug is listed, hospitals are willing to prescribe at scale and patients pay less out of pocket. Seventeen products on the list signals that Innovent's commercial pipeline has real breadth.
•
This reflects an accelerating shift from R&D-driven to commercialization-driven growth.
03

What does each new drug target?

•
Xinermei® (mazdutide): a GCG/GLP-1 dual-agonist injection competing in the same lane as semaglutide, aimed at weight loss and type-2 diabetes.
•
Xinmeiyue® (picankibart): an IL-23 inhibitor for psoriasis and other autoimmune conditions. Dabaixing® (ipilimumab): a CTLA-4 inhibitor for combination immunotherapy in kidney cancer, colorectal cancer, and other solid tumors.
•
Weifutai® (quizartinib): targets FLT3-mutant acute myeloid leukemia — a blood cancer driven by a specific gene mutation.
•
This means → the four drugs sit in four distinct therapeutic lanes. Innovent is not betting on a single blockbuster — it is spreading across multiple fields at once.
04

Does getting listed guarantee strong sales?

•
Not necessarily. Reimbursement solves the "can it be covered?" question. But between listing and actual volume growth lie hospital formulary adoption, physician prescribing habits, and patient awareness.
•
Innovent itself acknowledges that converting payer access into clinical uptake is the key checkpoint for proving commercial value.
•
In plain terms = winning a spot on the catalogue is like getting shelf space in a supermarket — the product is on the shelf, but how much consumers buy still depends on marketing and the competitive landscape. Catalogue inclusion is the starting line, not the finish.

市场有风险,内容仅供研究参考,不构成投资建议。

相关标的

2
  • HK inno.N195940.KR+1.4%

    Central subject of the event. Seven innovative drugs newly included in medical insurance, expanding coverage to 17 drugs. Payment-side access directly impacts product volume growth expectations.

  • Eli LillyLLY.US+1.3%

    Eli Lilly is Innovent Biologics' core partner in the GLP-1 space. The inclusion of mazdutide in medical insurance may affect the GLP-1 competitive landscape and Lilly's China market expectations.